Information  X 
Enter a valid email address

Astrazeneca PLC Ord (AZN)

Date Time Source Announcement
20 May 2022 4:00 pm
RNS
Director/PDMR Shareholding
09 May 2022 1:00 pm
RNS
Appointment of joint corporate brokers
06 May 2022 4:00 pm
RNS
Director/PDMR Shareholding
05 May 2022 7:10 am
RNS
Enhertu approved in US for 2L HER2+ breast cancer
  7:05 am
RNS
Farxiga HFpEF Phase III trial met primary endpoint
  7:00 am
RNS
Ultomiris NMOSD Ph. III trial met primary endpoint
04 May 2022 7:00 am
RNS
Imfinzi combo granted Priority Review for BTC
03 May 2022 3:00 pm
RNS
Total Voting Rights
29 Apr 2022 5:30 pm
RNS
Result of AGM
  7:05 am
RNS
AstraZeneca plans new R&D centre in Massachusetts
  7:00 am
RNS
First quarter 2022 results
28 Apr 2022 7:00 am
RNS
Ultomiris approved in the US for adults with gMG
27 Apr 2022 7:00 am
RNS
Enhertu granted BTD for HER2-low breast cancer
25 Apr 2022 7:00 am
RNS
Tremelimumab US Priority Review for Imfinzi combo
19 Apr 2022 7:00 am
RNS
Enhertu granted Priority Review for HER2m NSCLC
01 Apr 2022 3:00 pm
RNS
Total Voting Rights
29 Mar 2022 7:00 am
RNS
Ondexxya approved in Japan for FXai reversal
28 Mar 2022 7:00 am
RNS
Evusheld approved in the EU for COVID-19
25 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
24 Mar 2022 6:00 pm
RNS
Evusheld Positive EU CHMP Opinion
  7:00 am
RNS
Update on CALLA Phase III trial for Imfinzi
23 Mar 2022 11:00 am
RNS
Notice of AGM
17 Mar 2022 7:00 am
RNS
Settlement of patent litigation for Ultomiris
14 Mar 2022 7:05 am
RNS
Lynparza approved in US for early breast cancer
  7:00 am
RNS
Update on US review of Fasenra in nasal polyps
09 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
07 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
01 Mar 2022 3:30 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
AstraZeneca and Neurimmune close deal for NI006
23 Feb 2022 7:00 am
RNS
Filing of Form 20-F with SEC
22 Feb 2022 11:00 am
RNS
Chair succession planning update and Annual Report
21 Feb 2022 7:00 am
RNS
Enhertu improves PFS and OS in HER2-low BC
16 Feb 2022 7:00 am
RNS
Saphnelo approved in EU for SLE
15 Feb 2022 7:00 am
RNS
Lynparza combo delays progression risk in prostate
11 Feb 2022 3:30 pm
RNS
Director/PDMR Shareholding
10 Feb 2022 7:00 am
RNS
AZN: Full year and Q4 2021 results
01 Feb 2022 3:00 pm
RNS
Total Voting Rights
19 Jan 2022 7:05 am
RNS
Imfinzi improves survival in biliary tract cancer
  7:00 am
RNS
Imfinzi combo shows unprecedented survival in HCC
17 Jan 2022 7:00 am
RNS
Enhertu granted Priority Review for breast cancer
07 Jan 2022 7:00 am
RNS
AstraZeneca and Neurimmune sign deal for NI006
05 Jan 2022 7:00 am
RNS
Transfer of rights to Eklira, Duaklir completed
04 Jan 2022 3:00 pm
RNS
Total Voting Rights
29 Dec 2021 7:00 am
RNS
AstraZeneca and Ionis close eplontersen deal
21 Dec 2021 7:00 am
RNS
Ultomiris accepted for FDA Priority Review for gMG
20 Dec 2021 7:05 am
RNS
Tezspire approved in the US for severe asthma
  7:00 am
RNS
Saphnelo recommended for EU approval for SLE
15 Dec 2021 3:00 pm
RNS
Director/PDMR Shareholding
09 Dec 2021 7:00 am
RNS
Evusheld US FDA EUA
07 Dec 2021 7:00 am
RNS
AstraZeneca, Ionis to collaborate on eplontersen
01 Dec 2021 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
30 Nov 2021 7:00 am
RNS
Lynparza granted FDA Priority Review for OlympiA
15 Nov 2021 4:00 pm
RNS
Director/PDMR Shareholding
12 Nov 2021 7:00 am
RNS
AZN: Year to date and Q3 2021 results
01 Nov 2021 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
AstraZeneca to transfer rights to Eklira, Duaklir
25 Oct 2021 7:00 am
RNS
Imfinzi improved survival in biliary tract cancer
18 Oct 2021 7:00 am
RNS
AZ recommends ADS holders reject mini-tender offer

a d v e r t i s e m e n t